- Home
- PENN vs KNSA Comparison
PENN vs KNSA Comparison
Compare PENN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- KNSA
- Stock Information
- Founded
- PENN 1972
- KNSA 2015
- Country
- PENN United States
- KNSA United Kingdom
- Employees
- PENN N/A
- KNSA N/A
- Industry
- PENN Hotels/Resorts
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- PENN Consumer Discretionary
- KNSA Health Care
- Exchange
- PENN Nasdaq
- KNSA Nasdaq
- Market Cap
- PENN 2.8B
- KNSA 2.6B
- IPO Year
- PENN 1994
- KNSA 2018
- Fundamental
- Price
- PENN $16.18
- KNSA $38.49
- Analyst Decision
- PENN Buy
- KNSA Strong Buy
- Analyst Count
- PENN 16
- KNSA 7
- Target Price
- PENN $22.80
- KNSA $49.71
- AVG Volume (30 Days)
- PENN 3.1M
- KNSA 541.3K
- Earning Date
- PENN 11-06-2025
- KNSA 10-28-2025
- Dividend Yield
- PENN N/A
- KNSA N/A
- EPS Growth
- PENN N/A
- KNSA N/A
- EPS
- PENN N/A
- KNSA 0.47
- Revenue
- PENN $6,745,700,000.00
- KNSA $597,973,000.00
- Revenue This Year
- PENN $8.36
- KNSA $62.63
- Revenue Next Year
- PENN $5.50
- KNSA $29.93
- P/E Ratio
- PENN N/A
- KNSA $82.56
- Revenue Growth
- PENN 7.33
- KNSA 55.68
- 52 Week Low
- PENN $13.25
- KNSA $17.82
- 52 Week High
- PENN $23.08
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- PENN 37.15
- KNSA 54.37
- Support Level
- PENN $16.25
- KNSA $36.56
- Resistance Level
- PENN $18.28
- KNSA $41.28
- Average True Range (ATR)
- PENN 0.55
- KNSA 1.58
- MACD
- PENN -0.05
- KNSA -0.27
- Stochastic Oscillator
- PENN 11.33
- KNSA 53.22
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.